You are viewing the site in preview mode

Skip to main content

Call for papers: Impact of COVID-19 on clinical trials

Trials is inviting submission of manuscripts, long and short, including Letters and Commentaries detailing the enforced changes to trial design; trial management; recruitment; consent process; intervention delivery and follow up as a result of the COVID-19 pandemic. We also welcome submission of Updates to protocols previously published in Trials that describe changes made because of the COVID-19 pandemic.

  1. The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying its 58 trial sites ac...

    Authors: Silke van Koningsbruggen-Rietschel, Fiona Dunlevy, Veerle Bulteel, Kate Hayes, Anne Verbrugge, Hettie M. Janssens, Nadine Dufeu, Nicholas J. Simmonds, Lieven J. Dupont and Damian G. Downey

    Citation: Trials 2021 22:578

    Content type: Commentary

    Published on:

  2. Globally, the ongoing pursuit in exploring an effective drug to combat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has not met with significant success to date. Indian traditional medici...

    Authors: Anurag Srivastava, Manickavasagam Rengaraju, Saurabh Srivastava, Vimal Narayanan, Vivek Gupta, Rashmi Upadhayay, Jitender Kumar, Sathiyarajeswaran Parameswaran, KanakavalliKadarkarai and AarthiVelmurugan

    Citation: Trials 2021 22:570

    Content type: Research

    Published on:

  4. The COVID-19 pandemic has posed challenges to the conduct of clinical trials. Strategies for overcoming common challenges to non-COVID-19 trial continuation have been reported, but this literature is limited t...

    Authors: Bronwyn Myers, Claire van der Westhuizen, Megan Pool, Nancy Hornsby and Katherine R. Sorsdahl

    Citation: Trials 2021 22:440

    Content type: Commentary

    Published on:

  5. After the SARS-CoV-2 pandemic took hold in the UK, the ActWELL trial team’s plans to present the trial results to participants and other stakeholders had to change. Instead of face-face events, three online ev...

    Authors: Hanne Bruhn, Annie S. Anderson, Amy Hickman, E. Jane Macaskill and Shaun Treweek

    Citation: Trials 2021 22:381

    Content type: Letter

    Published on:

    The Research to this article has been published in Trials 2020 21:484

  6. The LEAP-MS (Lifestyle, Exercise and Activity Package for People living with Progressive Multiple Sclerosis) study has developed an individualised supported self-management approach for physical activity for p...

    Authors: Rachel Lowe, Christy Barlow, Barry Lloyd, Julie Latchem-Hastings, Vincent Poile, Charlotte Scoble, Andrew Dean-Young, Kate Button, Rebecca Playle and Monica Busse

    Citation: Trials 2021 22:286

    Content type: Commentary

    Published on:

  9. There is a dearth of literature on best practices for managing clinical trials, and little is understood on the role of the clinical trial manager. The COVID-19 pandemic has brought this into focus, and the co...

    Authors: Frances Shiely, Jean Foley, Amy Stone, Emma Cobbe, Shaunagh Browne, Ellen Murphy, Maeve Kelsey, Joanne Walsh-Crowley and Joseph A. Eustace

    Citation: Trials 2021 22:62

    Content type: Commentary

    Published on:

  10. The aim of this study is to assess the effectiveness and safety of glucocorticoid infusion pulse therapy to improve the clinical outcomes of patients with COVID-19 pneumonia with elevated inflammatory biomarkers.

    Authors: Iñigo Les Bujanda, Jose Loureiro-Amigo, Ferran Capdevila Bastons, Iñaki Elejalde Guerra, Javier Anniccherico Sánchez, Anna Murgadella-Sancho, Ruth García Rey, Julián Librero López and Julio Sánchez Álvarez

    Citation: Trials 2021 22:43

    Content type: Letter

    Published on:

  11. As of December, 1st, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected peopl...

    Authors: W. Dioh, M. Chabane, C. Tourette, A. Azbekyan, C. Morelot-Panzini, L. A. Hajjar, M. Lins, G. B. Nair, T. Whitehouse, J. Mariani, M. Latil, S. Camelo, R. Lafont, P. J. Dilda, S. Veillet and S. Agus

    Citation: Trials 2021 22:42

    Content type: Letter

    Published on:

  12. The COVID-19 pandemic has presented unique challenges for the clinical trial community, both in the rapid establishment of COVID-19 clinical trials and many existing non-COVID-19 studies either being temporari...

    Authors: Eleanor J. Mitchell, Khaled Ahmed, Suzanne Breeman, Seonaidh Cotton, Lynda Constable, Gillian Ferry, Kirsteen Goodman, Helen Hickey, Garry Meakin, Katy Mironov, Niamh Quann, Natalie Wakefield and Alison McDonald

    Citation: Trials 2020 21:784

    Content type: Commentary

    Published on:

  13. Whilst the issues around early termination of randomised controlled trials (RCTs) are well documented in the literature, trials can also be temporarily suspended with the real prospect that they may subsequent...

    Authors: Lynda Constable, Tracey Davidson, Suzanne Breeman, Seonaidh Cotton, Alison McDonald, Samantha Wileman and John Norrie

    Citation: Trials 2020 21:765

    Content type: Commentary

    Published on: